10 September 2021 - The UK MHRA has approved a marketing authorisation for Pfizer’s oral Janus kinase 1 inhibitor Cibinqo (abrocitinib) for the treatment of moderate to severe atopic dermatitis – the most common form of eczema.

The authorisation clears Cibinqo to treat the common inflammatory skin disease in adults and adolescents aged 12 years and over who are candidates for systemic therapy.

Read Pharma Times article